Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.950-5.350 for the period, compared to the consensus earnings per share estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $53.76 on Friday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business has a fifty day moving average of $50.16 and a 200 day moving average of $54.00. The firm has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 1 year low of $33.15 and a 1 year high of $65.53.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Piper Sandler lifted their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.